Iovance Biotherapeutics is trading 4.24% down now at $7.67 after no clear company-specific catalyst emerged in the August 31, 2026 search.
- August 21 inducement grants were not a material negative announcement.
- August 6 results showed approximately $99.3 million in quarterly revenue and continued Amtagvi demand.
- Broader markets are lower amid geopolitical, oil-price, and interest-rate concerns.